Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID06642441

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Led by Jiuda Zhao · Updated on 2025-01-17

100

Participants Needed

2

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effect of vitamin D supplementation on side effects experienced during adjuvant chemotherapy in patients with breast cancer. This Phase III randomized controlled trial focuses on whether adding vitamin D2 affects the occurrence of severe side effects during chemotherapy treatment. Both groups also receive standard chemotherapy, and the study aims to thoroughly assess adverse events related to the treatment. Participants are randomly assigned to one of two groups: one group receives standard chemotherapy along with vitamin D2 injections, administered before treatment and every three weeks during chemotherapy cycles; the other group receives only the standard chemotherapy regimen. The dosage of chemotherapy drugs may be adjusted based on the doctor's clinical judgment. Blood samples and imaging are collected before starting chemotherapy and after every two cycles to monitor effects. During the study, researchers will document and analyze the incidence of treatment-related adverse events of grade III or higher, as well as side effects using health status and fatigue scales from the start of chemotherapy to 21 days after the last cycle. The total participation includes multiple chemotherapy cycles over approximately 4 to 6 months, with ongoing monitoring of safety and treatment impact throughout this period.

CONDITIONS

Brief Title

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years with an ECOG performance status of 0-2
  • Primary diagnosis of breast cancer confirmed by pathological examination
  • Serum 25(OH)D levels less than 20 ng/ml (50 nmol/L)
  • No prior chemotherapy and planned for at least 4 cycles of adjuvant chemotherapy or combined targeted therapy
  • Life expectancy of at least 6 months
  • No uncontrolled benign diseases at recruitment
  • Complete clinical medical records
  • Willingness to sign informed consent form voluntarily
Not Eligible

You will not qualify if you...

  • History of invasive breast cancer
  • Prior systemic treatment for breast cancer
  • Known allergy to vitamin D or calcium compounds
  • Comorbidities affecting vitamin D or calcium balance or bone health
  • Vitamin D or calcium supplementation in the past 3 months
  • Presence of other tumors
  • Pregnant or lactating women
  • Individuals unwilling to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 to 6 months

Participants receive standard adjuvant chemotherapy cycles. One group also receives vitamin D2 injections before the start and every 3 weeks during chemotherapy until treatment completion. Blood samples and imaging are collected before treatment and after every two chemotherapy cycles.

Visits every 3 weeks during chemotherapy cycles

Follow-up

Duration - Approximately 3 weeks

Participants are monitored for side effects and adverse events for 21 days after the last chemotherapy cycle.

1 follow-up visit

Trial Site Locations

Total: 2 locations

1

Qinghai University Affiliated Hospital

Xining, Qinghai, China, 810000

Not Yet Recruiting

2

Qinghai University Affiliated Hospital

Xining, Qinghai, China, 810000

Actively Recruiting

Loading map...

Research Team

J

Jiuda Zhao

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here